HeartBeam, Inc. 8-K Summary
Business Context and Reporting Period
HeartBeam, Inc. filed a Current Report on Form 8-K dated March 7, 2023, reporting amendments to financing arrangements with Maverick Capital Partners, LLC. The company’s common stock and warrants trade on Nasdaq under BEAT and BEATW, respectively.
Financing and Key Financial Metrics
- The Securities Purchase Agreement was amended to reduce the maximum common-stock financing from $5.0 million to $4.0 million.
- Under a March 7 drawdown notice, HeartBeam agreed to issue 200,105 common shares for gross proceeds of $500,000. The shares were expected to be delivered on March 9, 2023.
- The shares are priced at 75% of the average volume-weighted average price during the applicable drawdown pricing period.
- The Note Purchase Agreement was amended to reduce the maximum principal amount of convertible notes from $5.0 million to $4.0 million.
- Total availability under the equity and convertible-note agreements is up to $4.0 million in aggregate and may consist of any combination of the two instruments.
- HeartBeam issued a $500,000 convertible note on March 1, 2023, bearing interest at 6% annually, and repaid the $500,000 principal plus accumulated interest on March 7, 2023.
- The filing does not provide revenue, profit, cash-flow, margin, debt-balance, or liquidity metrics beyond these financing transactions.
Material Changes, Outlook, and Risks
The principal material changes were the reduction of aggregate financing availability from $5.0 million to $4.0 million under each agreement and the replacement of the short-term $500,000 convertible note with a $500,000 equity drawdown. The financing provides potential additional capital but may result in equity dilution and variable share issuance prices. The filing does not provide operating guidance, forecasts, management commentary, or a broader liquidity assessment.
Investor Verification Items
- Verify delivery and registration of the 200,105 shares and the final proceeds after expenses.
- Confirm repayment of the $500,000 convertible note and the amount of interest paid.
- Review the amendments for remaining drawdown conditions, conversion terms, and aggregate availability under the $4.0 million facility.
- Assess dilution from the shares issued and any future equity or convertible-note financing.
- Review the related prospectus supplement and the company’s subsequent filings for additional draws or changes to financing terms.